Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced today that it has learned that Osmotica Pharmaceuticals LLC and Vertical Pharmaceuticals LCC (Osmotica) filed an action in Delaware federal court on February 16, 2018 requesting a declaratory judgment that Osmotica's newly-approved product O...
Feb 19, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time...
Feb 13, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option to purchase an aggregate of 42,250 shares of the company's common stock, at a per share exercise price of $36.49, the closing tra...
Feb 9, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson's disease patients taking amantadine immediate release (IR) who were still experiencing dyskinesia and enrolled into EASE LID 2, the long-term, ongoing Phase 3 open-label study of GOCOVRI™ (ama...
Feb 8, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Founder, Chairman and Chief Executive Officer of Adamas, is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York on Thursday, February 15, 2018 at 1:00 p.m. Easte...
Feb 7, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine) extended release capsules in multiple sclerosis (MS) patients with walking impairment were published online in Multiple Sclerosis Journal. Clinical da...
Feb 1, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the closing of its previously announced underwritten public offering of its common stock. Adamas sold 3,000,000 shares of its common stock, and the underwriters have exercised their option in full to purchase an additional 450,000 shar...
Jan 29, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $41.50 per share. The aggregate gross proceeds from this offering are expected to be $124,500,000, before deducting the...
Jan 23, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer $85 million of its common stock in an underwritten public offering. Adamas expects to grant the underwriters a 30-day option to purchase up to an additional $12.75 million of its common stock in connection with t...
Jan 22, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended release capsules, for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomita...
Jan 8, 2018 General Releases HTML PDF
EMERYVILLE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted 64 new employees the option to purchase an aggregate of 77,550 shares of the company's common stock, at a per share exercise price of $35.76, the closing tradi...
Dec 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences: Richard A. King, the company's Chief Operating Officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesda...
Nov 22, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option to purchase an aggregate of 15,300 shares of the company's common stock, at a per share exercise price of $27.00, the closing tra...
Nov 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30, 2017. "We are thrilled that GOCOVRI (amantadine) extended release capsules is approved for Parkinson's disease patients with dyskinesia receiving l...
Nov 2, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report third quarter 2017 financial results on Thursday, November 2, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the ...
Oct 26, 2017 General Releases HTML PDF
Page:
...
Next Last